ConvaTec Group PLC
LSE:CTEC

Watchlist Manager
ConvaTec Group PLC Logo
ConvaTec Group PLC
LSE:CTEC
Watchlist
Price: 235.8 GBX 2.25% Market Closed
Market Cap: 4.8B GBX
Have any thoughts about
ConvaTec Group PLC?
Write Note

Operating Margin
ConvaTec Group PLC

13.3%
Current
12%
Average
4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
13.3%
=
Operating Profit
292.4m
/
Revenue
2.2B

Operating Margin Across Competitors

Country UK
Market Cap 4.8B GBP
Operating Margin
13%
Country JP
Market Cap 6.8T JPY
Operating Margin
28%
Country CH
Market Cap 37.9B CHF
Operating Margin
13%
Country DK
Market Cap 200.9B DKK
Operating Margin
27%
Country US
Market Cap 16.9B USD
Operating Margin
17%
Country KR
Market Cap 9.9T KRW
Operating Margin
-245%
Country CA
Market Cap 6.9B USD
Operating Margin
4%
Country CN
Market Cap 48.6B CNY
Operating Margin
46%
Country US
Market Cap 6.3B USD
Operating Margin
32%
Country US
Market Cap 6.1B USD
Operating Margin
12%
Country CH
Market Cap 4.9B CHF
Operating Margin
14%
No Stocks Found

ConvaTec Group PLC
Glance View

Market Cap
4.8B GBX
Industry
Health Care

ConvaTec Group PLC is a global medical technology company that specializes in the development and marketing of advanced products for wound care, ostomy care, continence care, and critical care. Founded in 1978 and headquartered in the UK, ConvaTec has established itself as a leader in the healthcare space, relentlessly focusing on innovative solutions that enhance patient outcomes and streamline healthcare delivery. With a diverse portfolio of trusted brands such as AQUACEL® and Versiva®, the company provides essential products that cater to the needs of patients with chronic, acute, and complex wounds as well as those requiring ostomy care. The company's growth trajectory has been bolstered by strategic investments in research and development, positioning it as a pioneer in integrating cutting-edge technologies into its offerings. As an investor, ConvaTec presents a compelling opportunity driven by increasing demand in the healthcare sector, notably due to an aging population, rising prevalence of chronic conditions, and heightened awareness of infection control. The company has demonstrated resilience and adaptability in navigating market fluctuations, evidenced by its strong revenue growth and operational improvements. With a robust pipeline of innovative products and a commitment to sustainability, ConvaTec is well-positioned to capitalize on emerging trends in healthcare. As healthcare evolves, its focus on delivering high-quality solutions not only enhances patient experiences but also promises to yield solid returns for investors looking to support the future of medical innovation.

CTEC Intrinsic Value
278.46 GBX
Undervaluation 15%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
13.3%
=
Operating Profit
292.4m
/
Revenue
2.2B
What is the Operating Margin of ConvaTec Group PLC?

Based on ConvaTec Group PLC's most recent financial statements, the company has Operating Margin of 13.3%.